[Pe-21] 一般演題ポスターセッション（英語）21 末梢神経障害 02

[Pe-21-12] Global Open-label Extension: 24-month Data of Patisiran in Patients with hATTR Amyloidosis

^○植田 光晴¹, D Adams², A González-Duarte³, E Mauricio⁴, T Brannagan⁵, T Coelho⁶, J Wixner⁷, Schmidt Schmidt⁸, E Berber⁹, MT Sweetser¹⁰, MT White¹⁰, JJ Wang⁹, M Polydefkis¹¹ (1.熊本大学病院 脳神経内科, 2.National Reference Center for FAP (NNERF)/ APHP/ INSERM U 1195/ CHU Bicêtre, Le Kremlin Bicêtre, France, 3.Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, 4.Mayo Clinic, Jacksonville, FL, USA, 5.Department of Neurology, Columbia University, New York City, NY, USA, 6.Hospital de Santo António, Porto, Portugal, 7.Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden, 8.University Hospital Muenster, Muenster, Germany, 9.Former affiliation of Alnylam Pharmaceuticals, Cambridge, USA, 10.Alnylam Pharmaceuticals, Cambridge, USA, 11.Johns Hopkins University, Baltimore, USA)